Starpharma Holdings Limited (AU:SPL) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Starpharma Holdings Limited is making significant progress in developing clinical pathways for its lead candidates, DEP® SN38 and DEP® cabazitaxel, as it continues to explore commercialization opportunities. The company is advancing its DEP® HER2 radiodiagnostic program and evaluating collaboration prospects, supported by a strong cash position of $24 million. Key initiatives also include expanding revenue from VivaGel® BV and Viraleze™, despite withdrawing the SPL7013 Nasal Spray application in Australia to focus on higher-priority programs.
For further insights into AU:SPL stock, check out TipRanks’ Stock Analysis page.